Heterodimerisation of G protein-coupled receptors: Implications for drug design and ligand screening

Expert Opinion on Drug Discovery

Volumn 5, Issue 5, 2010, Pages 461-474

  Del Burgo, Laura Saenz ^a   Milligan, Graeme ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Arrestin; Bioluminescence resonance energy transfer; Dimer Translocation Assay; DimerScreen ; Drug development; Enzyme Complementation Assay

Indexed keywords

BETA ARRESTIN; BETA GALACTOSIDASE; G PROTEIN COUPLED RECEPTOR;

BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; DIMERIZATION; DRUG DESIGN; DRUG SCREENING; LIGAND BINDING; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW;

EID: 77951668878     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441003720467     Document Type: Review

References (91)

1. Spiegel AM. Defects in G protein-coupled signal transduction in human disease. Annu Rev Physiol 1996;58:143-170
2. Bockaert J, Pin JP. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J 1999;18(7):1723-1729
3. Han Y, Moreira IS, Urizar E, et al. Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat Chem Biol 2009;5(9):688-695
4. Reddy PS, Corley RB. Assembly, sortin and exit of oligomeric proteins from the endoplasmic reticulum. Bioessays 1998;20(7):546-554
5. Angers S, Salahpour A, Joly E, et al. Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci USA 2000;97(7):3684-3689
6. Cheng ZJ, Miller LJ. Agonist-dependen dissociation of oligomeric complexes of G protein-coupled cholecystokinin receptors demonstrated in living cells using bioluminescence resonance energy transfer. J Biol Chem 2001;276(51):48040-48047
7. Kroeger KM, Hanyaloglu AC, Seeber RM, et al. Constitutive and agonist-dependent homo-oligomerization of the thyrotropin-releasing hormone receptor. Detection in living cells using bioluminescence resonance energy transfer. J Biol Chem 2001;276(16):12736-12743
8. Pin JP, Neubig R, Bouvier M, et al. International Union of Basic and Clinic Pharmacology. LXVII. Recommendation for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev 2007;59(1):5-13
9. Ferre S, Baler R, Bouvier M, et al. Building a new conceptual framework f receptor heteromers. Nat Chem Biol 2009;5(3):131-134
10. George SR, O'Dowd BF, Lee SP. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov 2002;1(10):808-820
11. Lee SP, O'Dowd BF, Ng GY, et al. Inhibition of cell surface expression by mutant receptors demonstrates that D2 dopamine receptors exist as oligomers in the cell. Mol Pharmacol 2000;58(1):120-128
12. Chidiac P, Green MA, Pawagi AB, Wells JW. Cardiac muscarinic receptors. Cooperativity as the basis for multiple states of affinity. Biochemistry 1997;36(24):7361-7379 (Pubitemid 27262359)
13. Lopez-Gimenez JF, Canals M, Pediani JD, Milligan G. The alpha1b-adrenoceptor exists as a higher-order oligomer: effective oligomerization is required for receptor maturation, surface delivery, and function. Mol Pharmacol 2007;71(4):1015-1029
14. Carrillo JJ, Lopez-Gimenez JF, Milligan G. Multiple interactions between transmembrane helices generate the oligomeric alpha1b-adrenoceptor. Mol Pharmacol 2004;66(5):1123-1137
15. Liang Y, Fotiadis D, Filipek S, et al. Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes. J Biol Chem 2003;278(24):21655-21662
16. Overton MC, Chinault SL, Blumer KJ. Oligomerization, biogenesis, and signaling is promoted by a glycophorin A-like dimerization motif in transmembrane domain 1 of a yeast G protein-coupled receptor. J Biol Chem 2003;278(49):49369-49377
17. Guo W, Shi L, Filizola M, et al. Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc Natl Acad Sci USA 2005;102(48):17495-17500
18. Thevenin D, Lazarova T, Roberts MF, Robinson CR. Oligomerization of the fifth transmembrane domain from the adenosine A2A receptor. Protein Sci 2005;14(8):2177-2186
19. White JH, Wise A, Main MJ, et al. Heterodimerization is required for the formation of a functional GABA(B) receptor. Nature 1998;396(6712):679-682
20. AbdAlla S, Zaki E, Lother H, Quitterer U. Involvement of the amino terminus of the B(2) receptor in agonist-induced receptor dimerization. J Biol Chem 1999;274(37):26079-26084
21. Cvejic S, Devi LA. Dimerization of the delta opioid receptor: implication for a role in receptor internalization. J Biol Chem 1997;272(43):26959-26964
22. AbdAlla S, Lother H, el Massiery A, Quitterer U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 2001;7(9):1003-1009
23. Shioda T, Nakayama EE, Tanaka Y, et al. Naturally occurring deletional mutation in the C-terminal cytoplasmic tail of CCR5 affects surface trafficking of CCR5. J Virol 2001;75(7):3462-3468
24. Wilson S, Wilkinson G, Milligan G. The CXCR1 and CXCR2 receptors form constitutive homo-and heterodimers selectively and with equal apparent affinities. J Biol Chem 2005;280(31):28663-28674
25. Canals M, Lopez-Gimenez JF, Milligan G. Cell surface delivery and structural re-organization by pharmacological chaperones of an oligomerization-defective alpha(1b)-adrenoceptor mutant demonstrates membrane targeting of GPCR oligomers. Biochem J 2009;417(1):161-172
26. Brown D, Breton S. Sorting proteins to their target membranes. Kidney Int 2000;57(3):816-824
27. Kim PS, Arvan P. Endocrinopathies in the family of endoplasmic reticulum (ER) storage diseases: disorders of protein trafficking and the role of ER molecular chaperones. Endocr Rev 1998;19(2):173-202
28. Breit A, Lagace M, Bouvier M. Hetero-oligomerization between beta2-and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties. J Biol Chem 2004;279(27):28756-28765
29. Xu J, He J, Castleberry AM, et al. Heterodimerization of alpha 2A-and beta 1-adrenergic receptors. J Biol Chem 2003;278(12):10770-10777
30. Stanasila L, Perez JB, Vogel H, Cotecchia S. Oligomerization of the alpha 1a-and alpha 1b-adrenergic receptor subtypes. Potential implications in receptor internalization. J Biol Chem 2003;278(41):40239-40251
31. George SR, Fan T, Xie Z, et al. Oligomerization of mu-and delta-opioid receptors. Generation of novel functional properties. J Biol Chem 2000;275(34):26128-26135
32. Lee SP, So CH, Rashid AJ, et al. Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal. J Biol Chem 2004;279(34):35671-35678
33. Hilairet S, Bouaboula M, Carriere D, et al. Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. J Biol Chem 2003;278(26):23731-23737
34. Jordan BA, Devi LA. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 1999;399(6737):697-700
35. Waldhoer M, Fong J, Jones RM, et al. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci USA 2005;102(25):9050-9055
36. Milasta S, Pediani J, Appelbe S, et al. Interactions between the Mas-related receptors MrgD and MrgE alter signalling and trafficking of MrgD. Mol Pharmacol 2006;69(2):479-491
37. Hosoi T, Koguchi Y, Sugikawa E, et al. Identification of a novel human eicosanoid receptor coupled to G(i/o). J Biol Chem 2002;277(35):31459-31465
38. Takeda S, Yamamoto A, Okada T, et al. Identification of surrogate ligands for orphan G protein-coupled receptors. Life Sci 2003;74(2-3):367-377
39. Wenzel-Seifert K, Seifert R. Properties of Arg389-beta1-adrenoceptor- Gsalpha fusion proteins: comparison with Gly389-beta1-adrenoceptor-Gsalpha fusion proteins. Receptors Channels 2003;9(5):315-323
40. Milligan G. Insights into ligand pharmacology using receptor-G-protein fusion proteins. Trends Pharmacol Sci 2000;21(1):24-28
41. Milligan G. The use of receptor G-protein fusion proteins for the study of ligand activity. Receptors Channels 2002;8(5-6):309-317
42. Milligan G, Feng GJ, Ward RJ, et al. G protein-coupled receptor fusion proteins in drug discovery. Curr Pharm Des 2004;10(17):1989-2001
43. Milligan G, Parenty G, Stoddart LA, Lane JR. Novel pharmacological applications of G-protein-coupled receptor-G protein fusions. Curr Opin Pharmacol 2007;7(5):521-526
44. Fong CW, Milligan G. Analysis of agonist function at fusion proteins between the IP prostanoid receptor and cognate, unnatural and chimaeric G-proteins. Biochem J 1999;342(Pt 2):457-463
45. Barclay E, O'Reilly M, Milligan G. Activation of an alpha2A-adrenoceptor- Galphao1 fusion protein dynamically regulates the palmitoylation status of the G protein but not of the receptor. Biochem J 2005;385(Pt 1):197-206
46. Stoddart LA, Brown AJ, Milligan G. Uncovering the pharmacology of the G protein-coupled receptor GPR40: high apparent constitutive activity in guanosine 5¢-O-(3-[35S]thio)triphosphate binding studies reflects binding of an endogenous agonist. Mol Pharmacol 2007;71(4):994-1005
47. Zhang L, DiLizio C, Kim D, et al. The G12 family of G proteins as a reporter of thromboxane A2 receptor activity. Mol Pharmacol 2006;69(4):1433-1440
48. Bertin B, Freissmuth M, Jockers R, et al. Cellular signaling by an agonist-activated receptor/Gs alpha fusion protein. Proc Natl Acad Sci USA 1994;91(19):8827-8831
49. Hildebrandt JD. Bring your own G protein. Mol Pharmacol 2006;69(4):1079-1082
50. Perez DM, Karnik SS. Multiple signaling states of G-protein-coupled receptors. Pharmacol Rev 2005;57(2):147-161
51. Kenakin T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 2001;15(3):598-611
52. Urban JD, Clarke WP, von Zastrow M, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007;320(1):1-13
53. Lane JR, Powney B, Wise A, et al. Protean agonism at the dopamine D2 receptor: (S)-3-(3-hydroxyphenyl)-N-propylpiperidine is an agonist for activation of Go1 but an antagonist/inverse agonist for Gi1,Gi2, and Gi3. Mol Pharmacol 2007;71(5):1349-1359
54. Carrillo JJ, Pediani J, Milligan G. Dimers of class A G protein-coupled receptors function via agonist-mediated trans-activation of associated G proteins. J Biol Chem 2003;278(43):42578-42587
55. Pascal G, Milligan G. Functional complementation and the analysis of opioid receptor homodimerization. Mol Pharmacol 2005;68(3):905-915
56. Jans DA, Xiao CY, Lam MH. Nuclear targeting signal recognition: a key control point in nuclear transport? Bioessays 2000;22(6):532-544
57. Lu D, Yang H, Shaw G, Raizada MK. Angiotensin II-induced nuclear targeting of the angiotensin type 1 (AT1) receptor in brain neurons. Endocrinology 1998;139(1):365-375 (Pubitemid 28166330)
58. Lee DK, Lanca AJ, Cheng R, et al. Agonist-independent nuclear localization of the Apelin, angiotensin AT1, and bradykinin B2 receptors. J Biol Chem 2004;279(9):7901-7908
59. O'Dowd BF, Ji X, Alijaniaram M, et al. Dopamine receptor oligomerization visualized in living cells. J Biol Chem 2005;280(44):37225-37235
60. O'Dowd BF, Alijaniaram M, Ji X, et al. Using ligand-induced conformational change to screen for compounds targeting G-protein-coupled receptors. J Biomol Screen 2007;12(2):175-185
61. Juhasz JR, Hasbi A, Rashid AJ, et al. Mu-opioid receptor heterooligomer formation with the dopamine D1 receptor as directly visualized in living cells. Eur J Pharmacol 2008;581(3):235-243
62. Stoffel RH, 3rd, Pitcher JA, Lefkowitz RJ. Targeting G protein-coupled receptor kinases to their receptor substrates. J Membr Biol 1997;157(1):1-8
63. Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 2002;115(Pt 3):455-465
64. Shenoy SK, Lefkowitz RJ. Seven-transmembrane receptor signaling through beta-arrestin. Sci STKE 2005;2005(308):cm10-
65. Kendall RT, Luttrell LM. Diversity in arrestin function. Cell Mol Life Sci 2009;66(18):29:53-73
66. Gurevich VV, Gurevich EV. The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol Ther 2006;110(3):465-502
67. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science 2005;308(5721):512-517
68. Kovacs JJ, Hara MR, Davenport CL, et al. Arrestin development: emerging roles for beta-arrestins in developmental signaling pathways. Dev Cell 2009;17(4):443-458
69. Dromey JR, Pfleger KD. G protein coupled receptors as drug targets: the role of beta-arrestins. Endocr Metab Immune Disord Drug Targets 2008;8(1):51-61
70. Shenoy SK, Lefkowitz RJ. Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem J 2003;375(Pt 3):503-515
71. Oakley RH, Laporte SA, Holt JA, et al. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 2000;275(22):17201-17210
72. Kocan M, See HB, Seeber RM, et al. Demonstration of improvements to the bioluminescence resonance energy transfer (BRET) technology for the monitoring of G protein-coupled receptors in live cells. J Biomol Screen 2008;13(9):888-898
73. Hamdan FF, Audet M, Garneau P, et al. High-throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based beta-arrestin2 recruitment assay. J Biomol Screen 2005;10(5):463-475
74. Pfleger KD, Dalrymple MB, Dromey JR, Eidne KA. Monitoring interactions between G-protein-coupled receptors and beta-arrestins. Biochem Soc Trans 2007;35(Pt 4):764-766
75. Pfleger KD, Seeber RM, Eidne KA. Bioluminescence resonance energy transfer (BRET) for the real-time detection of protein-protein interactions. Nat Protocol 2006;1(1):337-345
76. Pfleger KD, Eidne KA. Illuminating insights into protein-protein interactions using bioluminescence resonance energy transfer (BRET). Nat Methods 2006;3(3):165-174
77. Milligan G, Bouvier M. Methods to monitor the quaternary structure of G protein-coupled receptors. FEBS J 2005;272(12):2914-2925 (Pubitemid 40904680)
78. Pfleger KD, Dromey JR, Dalrymple MB, et al. Extended bioluminescence resonance energy transfer (eBRET) for monitoring prolonged protein-protein interactions in live cells. Cell Signal 2006;18(10):1664-1670
79. Milligan G. Applications of bioluminescence-and fluorescence resonance energy transfer to drug discovery at G protein-coupled receptors. Eur J Pharm Sci 2004;21(4):397-405
80. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. Beta-arrestins and cell signaling. Annu Rev Physiol 2007;69:483-510
81. van Koppen CJ, Jakobs KH. Arrestin-independent internalization of G protein-coupled receptors. Mol Pharmacol 2004;66(3):365-367
82. Perroy J, Adam L, Qanbar R, et al. Phosphorylation-independent desensitization of GABA(B) receptor by GRK4. EMBO J 2003;22(15):3816-3824
83. Hanyaloglu AC, Seeber RM, Kohout TA, et al. Homo-and hetero- oligomerization of thyrotropin-releasing hormone (TRH) receptor subtypes. Differential regulation of beta-arrestins 1 and 2. J Biol Chem 2002;277(52):50422-50430
84. Ayoub MA, Pfleger KD. Recent advances in bioluminescence resonance energy transfer technologies to study GPCR heteromerization. Curr Opin Pharmacol 2010;10(1):44-52
85. Zabin I, Villarejo MR. Protein complementation. Annu Rev Biochem 1975;44:295-313
86. Juers DH, Jacobson RH, Wigley D, et al. High resolution refinement of beta-galactosidase in a new crystal form reveals multiple metal-binding sites and provides a structural basis for alpha-complementation. Protein Sci 2000;9(9):1685-1699
87. Eglen RM. Enzyme fragment complementation: a flexible high throughput screening assay technology. Assay Drug Dev Technol 2002;1(1 Pt 1):97-104
88. Eglen RM, Singh R. Beta galactosidase enzyme fragment complementation as a novel technology for high throughput screening. Comb Chem High Throughput Screen 2003;6(4):381-387
89. Buttner FH, Kumpf R, Menzel S, et al. Evaluation of the InteraX system technology in a high-throughput screening environment. J Biomol Screen 2005;10(5):485-494
90. Gouldson PR, Dean MK, Snell CR, et al. Lipid-facing correlated mutations and dimerization in G-protein coupled receptors. Protein Eng 2001;14(10):759-767
91. Bakker RA, Dees G, Carrillo JJ, et al. Domain swapping in the human histamine H1 receptor. J Pharmacol Exp Ther 2004;311(1):131-138